| Name | estrogen receptor |
|---|---|
| Synonyms | ER; ERA; ER alpha; ERalpha; ESR; ESR 1; ESR1; ESRA… |
| Name | sodium fluoride |
|---|---|
| CAS | sodium fluoride (NaF) |
| PubMed | Abstract | RScore(About this table) | |
|---|---|---|---|
| 18360603 | Maclaughlin EJ, Sleeper RB, McNatty D, Raehl CL: Management of age-related osteoporosis and prevention of associated fractures. Ther Clin Risk Manag. 2006 Sep;2(3):281-95. Drugs which have been shown to decrease the risk of age-related osteoporotic fractures include oral bisphosphonates ibandronate, and risedronate), intranasal calcitonin, estrogen receptor stimulators (eg, selective estrogen receptor modulators [raloxifene]), parathyroid hormone (teriparatide), sodium fluoride, and ranelate. |
7(0,0,1,2) | Details |
| 19758959 | Groheux D, Moretti JL, Giacchetti S, Hindie E, Teyton P, Cuvier C, Bousquet G, Misset JL, Boin C, Espie M: [PET/CT in breast cancer: an update] . Bull Cancer. 2009 Nov;96(11):1053-70. Roles of new tracers such as F-18 -L-thymidine (a marker of cell proliferation), 18--17- (marker of estrogen receptor) and sodium fluoride (marker of bone matrix) are also mentioned. |
6(0,0,1,1) | Details |
| 12530170 | Dimai HP, Pietschmann P, Resch H, Leb G, Klaushofer K: [Guidelines for drug therapy of postmenopausal osteoporosis] . Wien Med Wochenschr. 2002;152(23-24):596-612. In Austria, several pharmacologic options for treatment of osteoporosis are available, including bisphosphonates etidronate, risedronate), selective estrogen receptor modulators (raloxifene), calcitonins (salm-calcitonin, elcatonin), fluorides (sodium-fluoride, monofluorophosphate), anabolic steroids steroid derivates (tibolone), and hormone replacement therapy. |
6(0,0,1,1) | Details |
| 9689207 | Miller P, Lukert B, Broy S, Civitelli R, Fleischmann R, Gagel R, Khosla S, Lucas M, Maricic M, Pacifici R, Recker R, Sarran HS, Short B, Short MJ: Management of postmenopausal osteoporosis for primary care. Menopause. 1998 Summer;5(2):123-31. RESULTS: Prevention and treatment are discussed, including hormone replacement therapy and use of calcitonin, sodium fluoride, bisphosphonates, and serum estrogen receptor modulators. |
6(0,0,1,1) | Details |
| 9881322 | Netelenbos C: Osteoporosis: intervention options. Maturitas. 1998 Nov 16;30(3):235-9. During the last 3 years it has become clear that besides bisphosphonates and now perhaps the selective estrogen receptor modulators also show a good alternative as intervention option of postmenopausal osteoporosis. At this moment sodium fluoride is not the first choice in treatment of osteoporosis in general practice. |
1(0,0,0,1) | Details |
| 12589304 | Davidson MR: Pharmacotherapeutics for osteoporosis prevention and treatment. J Midwifery Womens Health. 2003 Jan-Feb;48(1):39-52. The following effective treatment options for women who have been diagnosed with the disease are discussed: bisphosphonates, calcitonin, and selective estrogen receptor modulators (SERMs). |
1(0,0,0,1) | Details |
| 11238469 | Rosen CJ, Bilezikian JP: Clinical review 123: Anabolic therapy for osteoporosis. . J Clin Endocrinol Metab. 2001 Mar;86(3):957-64. By acting at this site in the bone remodeling cycle, estrogens, selective estrogen receptor modulators, calcitonin, and the bisphosphonates all have the capacity to increase bone mineral density and to reduce the risk of new fractures. |
1(0,0,0,1) | Details |